A slightly lower sensitivity (67%) was reported for the detection of ALK/ROS1 fusions using amplicon-based sequencing in ctDNA of treatment-naïve NSCLC patients at the time of diagnosis [129]. This evidence concerns the gene ALK and non-small cell lung carcinoma.